Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation - Related Studies

Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation

This study has been completed.

Study NCT00130910. Last updated on November 13, 2007. Information provided by University of Washington

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections
		Helminthiasis

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Communicable Diseases
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Parasitic Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Albendazole
		Placebo

5	More general drug interventions related to this trial
		Anthelmintics
		Anti-Infective Agents
		Anticestodal Agents
		Antimitotic Agents
		Antineoplastic Agents
		Antiparasitic Agents
		Antiplatyhelmintic Agents
		Antiprotozoal Agents
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

6	Sponsors listed in this trial
		University of Washington
		Kenya Medical Research Institute
		University of Nairobi
		Kenyatta Hospital